ClinicalTrials.gg
CompletedNCT06084598Updated Mar 15, 2024

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

A Phase 1 interventional study of BMS-986446 and Placebo in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986446 in healthy participants including healthy participants of Japanese ethnicity.

02

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Healthy Participants
  • Healthy Japanese Participants
  • BMS-986446
  • PRX005
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be of Japanese ethnicity (both biological parents are ethnically Japanese) for Part 1 and Part 2, Panel 2. No limitations on ethnicity apply to Part 2, Panel 1
  • Participant is healthy, without any significant abnormalities in medical history, physical examination, ECGs, or clinical laboratory assessments determinations, as assessed by the investigator
  • (BMI) of at least 18 kg/m\^2 but no more than 32 kg/m\^2 at screening
  • Body weight between 45 kg and 110 kg

Exclusion criteria

Exclusion Criteria:

  • Any deviation from normal, as judged by the investigator
  • Any major surgery within 90 days of study drug administration
  • Participation in another interventional clinical trial concurrent with this study

Note: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BMS-986446

    Drug: BMS-986446

  • Experimental
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to Day 85

  2. Number of participants with vital sign abnormalities

    Time frame: Up to Day 85

  3. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 85

  4. Number of participants with physical examination abnormalities

    Time frame: Up to Day 85

  5. Number of participants with body weight abnormalities

    Time frame: Up to Day 85

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 85

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 85

  2. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to Day 85

  3. Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to Day 85

  4. Number of participants with anti-drug antibody (ADA)

    Time frame: Up to Day 85

  5. Geometric mean ratios of Cmax

    Time frame: Up to Day 85

  6. Geometric mean ratios of [AUC(0-T)]

    Time frame: Up to Day 85

  7. Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to Day 85

07

Study locations

1 site
  • Local Institution - 0001
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Mar 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 16, 2023
StartActual
Oct 12, 2023
Primary completionActual
Mar 8, 2024
CompletionActual
Mar 8, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06084598
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Oct 12, 2023
Primary completion
Mar 8, 2024
Completion
Mar 8, 2024
Last update
Mar 15, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moponetug

Start the discussion